Results from a late-stage trial of Eli Lilly's experimental weight-loss pill were disappointing, sending shares of the drugmaker tumbling.

Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected. It resulted in lower weight loss ...

Eli Lilly said this morning that its experimental obesity pill orforglipron fell short of expectations in a late-stage trial, delivering 11.2% weight loss over 72 weeks — less than the 15% to 21% ...

Fortinet, AppLovin, Airbnb, Duolingo and more stock were making big moves Thursday after the companies reported quarterly ...

Study participants lost an average of 12.4 per cent of their body weight over 72 weeks. View on euronews ...

Eli Lilly’s stock has reached a 52-week low, hitting $674.94, marking a significant drop from its 52-week high of $972.53. According to InvestingPro analysis, the company maintains strong fundamentals ...

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

Cancer vaccine experts are worried that if the Trump administration takes a hostile posture towards mRNA broadly, cancer ...

Eli Lilly, a renowned drug manufacturer, stated that its GLP-1 pill, orforglipron, assisted individuals in reducing 12.4% of their weight following 72 weeks in a late-stage study.The company ...

Eli Lilly shares fell as disappointing data on its new weight-loss pill overshadowed strong growth from the company’s current obesity medicine, which helped drive it to raise its yearly profit and ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

For comparison, Lilly's arch-rival in the weight-loss category, Novo Nordisk, is developing an oral formulation of ...